Table 1.

O-GlcNAcylated peptides presented by HLA B*0702 class I MHC molecules on leukemia

#SequenceStart–StopUniProtTumorSource protein
1aAPP(sts)AAAL405–414Q86TM6ALL, CLL1E3 Ubiquitin-protein ligase synoviolin
2bAPRGnVTSL60–68Q9NR96CLL1, CLL2Toll-like receptor 9
3APRtNGVAM187–195Q92567ALL, CLL1, CLL2Protein FAM168A
4APTsAAAL1116–1123Q86Z02ALLHomeodomain-interacting protein kinase 1
5APVsASASV1807–1815Q9Y520ALLProtein PRRC2C
6APVsSKSSL850–858Q86Z02ALL, CLL1, CLL2Homeodomain-interacting protein kinase 1
8HPMsTASQV345–353Q13492ALLClathrin assembly lymphoid myeloid leukemia
9cHP(sss)AAVL740–748Q86XN7ALL, CMLProline and serine-rich protein 1
10HP(sst)ASTAL3041–3050Q96T58ALLMsx2-interacting protein
11IPIsLHTSL1959–1967Q5JSZ5ALLProtein PRRC2B
12IPTsSVLSL710–718O15027ALLProtein transport protein Sec 16A
13dIPVsKPLSL104–112Q16621AML, ALL, CLL1Leucine zipper protein 1
14eIPVsSHNSL147–155Q06413AML, ALL, CLL1, JY, S, ToMyocyte-specific enhancer factor 2C
15fKPP(ts)QSSVL411–420Q5T6F2ALLUbiquitin-associated protein 2
16gKPPVsFFSL95–103Q6PKC3ALLThioredoxin domain containing protein 11
17hKPTLLYnVSL373–381P04220CLL1, CLL2Ig Mu heavy chain disease protein
18LPRN(st)MM335–342Q9NPI6ALLmRNA-decapping enzyme 1A
19LPTsLPSSL2464–2472P46531ALLNeurogenic locus notch homolog protein 1
20iMPVRPTtNTF218–227Q7Z3K3ALLpogo transposable element with ZNF domain
21NPVsLPSL831–838Q6VMQ6ALLActivating transcription factor 7-interacting protein
22jPPS(ts)AAAL405–414Q86TM6ALLE3 Ubiquitin-protein ligase synoviolin
23kRPPItQSSL382–390Q9P2N5ALL, SRNA binding protein 27
24lRPPQsSSVSL937–946O15027ALLProtein transport protein Sec 16A
25RPP(sss)QQL1758–1766Q8WYB5ALLHistone acetyltransferase KAT6B
26RPPVtKASSF341–350Q9Y2K5ALL, CLL1R3H domain containing protein 2
27RPVtASITTM927–936Q9ULH7ALL, CLL1, CLL2, SMKL/myocardin-like protein 2
28TPASsRAQTL2320–2329Q01082CLL1Spectrin beta chain, non-erythrocytic 1
29TPAsSSSAL875–883Q9NPG3ALL, CLL1Ubinucleain 1
30TPIsQAQKL3024–3032Q96L91ALLE1A-binding protein p400
31VPAsSTSTL576–584Q9NYV4ALL, CLL1Cyclin dependent kinase 12
32VPTtSSSL1284–1291Q14004ALLCyclin dependent kinase 13
33VPVsGTQGL93–101P23511ALLNuclear transcription factor Y subunit alpha
34VPVsNQSSL146–154Q14814ALLMyocyte-specific enhancer factor 2D
35VPVsSASEL596–603Q7Z2W4ALLZinc finger CCCH-type, antiviral 1
36VPVsVGPSL1157–1164Q86Z02ALLHomeodomain-interacting protein kinase 1
  • NOTE: Thirty-six peptides, often with multiple forms of glycosylation, were isolated from class I MHC molecules on several leukemias, cell lines, and healthy tissue. These sources are indicated as follows: CML; chronic myeloid leukemia, 1 and 2; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; J, JY cell line; S, spleen; To, tonsil; see Supplementary Table S1. Small letters, s, t, and n specify Ser, Thr, and Asn residues that are modified by O-GlcNAc unless otherwise indicated in a footnote. Parentheses enclose s and t residues that could be a site of GlcNAcylation. Samples were independently analyzed by MS at least 3 times.

  • aPeptide was detected in a total of five forms: single GlcNac, double GlcNAc, single hexose-GlcNAc, single GlcNAc (S6) + hexose- GlcNac (T5), and double hexose-GlcNAc.

  • bN5 is modified by N-linked hexose-GlcNAc.

  • cPeptide was detected in two forms, GlcNAc on S4 and two GlcNAcs on S4 and S5.

  • dPeptide was detected in two forms: GlcNAc (S4) and hexose-GlcNAc (S4).

  • ePeptide was detected in four forms: GlcNAc (S4), double GlcNAc (S4, S5), single hexose-GlcNAc (S4), and an acetyl-GlcNAc (S4).

  • fPeptide was detected in two forms: GlcNAc and hexose-GlcNAc (T4).

  • gS5 is modified by O-linked hexose-GlcNAc.

  • hN7 is modified by N-linked hexose-GlcNAc.

  • iPeptide was detected in two forms: hexose-GlcNAc and asymmetric di-methyl (R4) + hexose-GlcNAc (T7).

  • jT4 or S5 is modified by O-linked hexose-GlcNAc.

  • kPeptide was detected in four forms: GlcNAc (T5), mono-methyl (R1) + GlcNAc (T5), asymmetric di-methyl (R1) + GlcNAc (T5), and asymmetric di-methyl (R1) + acetyl-GlcNAc (T5).

  • lS5 is modified by O-linked hexose-GlcNAc.